| 摘要 |
Discloses Anti-HtrA1 antibodies binding to an epitope including N224, K248, or both of HtrA1. Also discloses associated methods of treating age-related macular degeneration, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, and polypoidal choroidal vasculopathy. |
